Articles By Jack Cush, MD
Biosimilar Reports – February 2017
Biosimilar reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists. Many of these items were compiled from news sources, journal articles and regulatory documents and are cited and linked within each section.
Read Article
The RheumNow Week in Review – 17 February 2017
Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.
Read Article
BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
Baricitinib is a novel inhibitor of Janus kinases JAK1 and JAK2 that has been extensively studied in rheumatoid arthritis (RA). Baricitinib (AKA Oluminant) was recently approved by the EMA for use in Europe at a once daily dose of 4 mg per day.
Read Article
Valeants Brodalumab FDA Approved for Psoriasis
FDA has approvesd the IL-17 targeted therapy Siliq (brodalumab) for moderate-severe plaque psoriasis.
Read Article
Baricitinib Approved in the EU for Use in Rheumatoid Arthritis
The European Commission has approved Eli Lilly's rheumatoid arthritis drug Olumiant (baricitinib) for use in Europe for RA patients with moderate-to-severe active disease in adults who have not responded one or more disease-modifying antirheumatic drugs.
Read Article
Crohn's Arthritis Linked to E. Coli Infection
Articular manifestations of Crohn's disease affects a significant number of patients with either oligoarticular or RA-like polyarthritis or spondyloarthritis.
Read Article
Immunosuppressives Fail to Benefit Early Skin Scleroderma
Treatment of systemic sclerosis is difficult, as there have few proven therapies capable of altering the course of the disease. Ideally, early intervention affords the optimal scenario wherein drug intervention can be proven to work.
Read Article
ACP Recommends a Drug-Free Approach to Back Pain
The American College of Physicians (ACP) recommends that physicians avoid prescribing drugs, especially narcotics, for patients with acute or subacute low back pain.
Read Article
The Negotiator
This is going to be my third visit with this patient and I’m not looking forward to it. In the first two, I discovered how sick she was and how, despite my handouts, efforts, insights and words, my educated medical expertise was totally wasted.
Read Article
The RheumNow Week in Review – 10 February 2017
Dr. Jack Cush discusses the news and reports from this week on RheumNow:
Read Article
